Zydus Lifesciences bags USFDA nod for Levothyroxine Sodium for Injection for myxedema coma treatment
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.
Ahmedabad: Pharma major, Zydus Lifesciences Limited, has received final approval for Levothyroxine Sodium for Injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the United States Food and Drug Administration (USFDA).
Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma. Myxedema coma is an extreme or decompensated form of hypothyroidism and while uncommon, is potentially lethal.
The group now has 354 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Lifesciences wins USFDA approval for Lubiprostone Capsules to treat constipation
Zydus Lifesciences Limited, Formerly known as Cadila Healthcare Limited, is an Indian Pharmaceutical company headquartered in Ahmedabad. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. It is primarily engaged in the manufacture of generic drugs.
Read also: Zydus Lifesciences Depression drug Doxepin Hydrochloride bags USFDA okay
